Join Adaptimmune for a virtual KOL event featuring Dr. Sandra P. D’Angelo, M.D. (Memorial Sloan Kettering Cancer Center) who will discuss the current treatment landscape for patients with sarcoma.

The event will focus on data presented at Connective Tissue Oncology Society (CTOS) 2024 annual meeting from the pivotal trial of letetresgene autoleucel (“lete-cel”), Adaptimmune’s engineered T-cell therapy for synovial sarcoma and MRCLS. The event will also highlight the impact of engineered cell therapies on the sarcoma treatment landscape. Tecelra^® was approved in August for the treatment of advanced synovial sarcoma and is the first engineered cell therapy approved by FDA for a solid tumor cancer.

A live question and answer session will follow the formal presentation.